Also trades as: 0KF3.L (LSE) · $vol 0M
PTN NASDAQ
Palatin Technologies, Inc.
1W: -7.6%
1M: -27.3%
3M: -15.3%
YTD: -41.9%
1Y: +18.9%
3Y: -88.7%
5Y: -98.4%
$9.33
+0.27 (+2.98%)
Weekly Expected Move ±15.6%
$6
$8
$9
$11
$12
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
7 relationships7
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2023-04-12
Earliest Filing
2025-11-06
Latest Filing
partner: 5
customer: 1
acquirer: 1
Counterparties (Filed by PTN)
7 relationshipsCompanies named in PTN's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| A.G.P./Alliance Global Partners | — | partner | Underwriter for the public offering of common stock and warrants. | 2025-11-06 | View |
| Boehringer Ingelheim International GmbH | — | partner | Counterparty to a business development collaboration that generated revenue. | 2025-11-06 | View |
| Boehringer Ingelheim International GmbH | — | partner | Research Collaboration, License and Patent Assignment Agreement for melanocortin receptor-targeted peptides | 2025-08-18 | View |
| A.G.P./Alliance Global Partners | — | partner | Sales agent and principal for the At the Market Issuance Sales Agreement | 2025-02-12 | View |
| Cosette Pharmaceuticals, Inc. | — | customer | Purchased the Vyleesi (Bremelanotide) product asset from the Company for $12 million upfront plus potential milestones. | 2024-02-01 | View |
| Cosette Pharmaceuticals, Inc. | — | acquirer | Acquired worldwide rights to Vyleesi from Palatin Technologies, Inc. | 2023-12-20 | View |
| Canaccord Genuity LLC | — | partner | Entered into an Equity Distribution Agreement to offer and sell the Company's common stock. | 2023-04-12 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-03 | Shareholder Vote; Exhibits | View | |
| 2026-05-18 | Delisting Notice; Regulation FD; Exhibits | View | |
| 2025-12-19 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-11-12 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-06 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-09-22 | Other Events; Financial Statements and Exhibits | View | |
| 2025-09-10 | Other Events | View | |
| 2025-08-18 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2025-08-11 | Regulation FD Disclosure | View | |
| 2025-08-08 | Material Modification to Rights of Security Holders; Amendments to Articles of Incorporation or Byla | View | |
| 2025-07-29 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View | |
| 2025-07-09 | Notice of Delisting or Transfer; Financial Statements and Exhibits | View | |
| 2025-06-13 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Amendments to Art | Agreement | View |
| 2025-05-08 | Entry into Material Definitive Agreement; Notice of Delisting or Transfer; Other Events; Financial S | Agreement | View |
| 2025-04-10 | Notice of Delisting or Transfer; Other Events; Financial Statements and Exhibits | View | |
| 2025-03-31 | Other Events; Financial Statements and Exhibits | View | |
| 2025-02-12 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-02-10 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Other Events; Fin | Agreement | View |
| 2024-12-16 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Regulation FD Dis | Agreement | View |
| 2024-11-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR